How to buy Aileron Therapeutics stock (ALRN)

Aileron Therapeutics is a biotechnology business based in the US. Aileron Therapeutics shares (ALRN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.23 – an increase of 27.43% over the previous week. Aileron Therapeutics employs 15 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Aileron Therapeutics stock

Buy Aileron Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Aileron Therapeutics stock price (NASDAQ: ALRN)

Use our graph to track the performance of ALRN stocks over time.

Aileron Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-26.

Latest market close	$2.23
52-week range	$1.61 - $7.42
50-day moving average more info button	$3.00
200-day moving average more info button	$3.45
Wall St. target price	$13.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-2.88

Is it a good time to buy Aileron Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aileron Therapeutics price performance over time

Historical closes compared with the close of $2.25 from 2024-12-26

1 week (2024-12-20)	28.57%
1 month (2024-11-27)	-17.88%
3 months (2024-09-27)	-38.36%
6 months (2024-06-27)	-22.41%

1 year (2023-12-27)	-31.19%
2 years (2022-12-27)	11.74%
3 years (2021-12-27)	10.878
5 years (2019-12-27)	12.4

Aileron Therapeutics financials

Gross profit TTM	$-17,008,000
Return on assets TTM	-25.86%
Return on equity TTM	-44.32%
Profit margin	0%
Book value	$1.41
Market Capitalization more info button	$47 million

TTM: trailing 12 months

Aileron Therapeutics share dividends

We're not expecting Aileron Therapeutics to pay a dividend over the next 12 months.

Have Aileron Therapeutics's shares ever split?

Aileron Therapeutics's shares were split on a 1:20 basis on 10 November 2022 . So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aileron Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Aileron Therapeutics shares which in turn could have impacted Aileron Therapeutics's share price.

Aileron Therapeutics share price volatility

Over the last 12 months, Aileron Therapeutics's shares have ranged in value from as little as $1.61 up to $7.42. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aileron Therapeutics's is 2.341. This would suggest that Aileron Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Aileron Therapeutics overview

Aileron Therapeutics, Inc. , a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc.

Frequently asked questions

null
What percentage of Aileron Therapeutics is owned by insiders or institutions?
Currently 0.65% of Aileron Therapeutics shares are held by insiders and 28.473% by institutions. How many people work for Aileron Therapeutics?
Latest data suggests 15 work at Aileron Therapeutics. When does the fiscal year end for Aileron Therapeutics?
Aileron Therapeutics's fiscal year ends in December. Where is Aileron Therapeutics based?
Aileron Therapeutics's address is: 12407 N. Mopac Expy., Austin, TX, United States, 78758 What is Aileron Therapeutics's ISIN number?
Aileron Therapeutics's international securities identification number is: US00887A1051 What is Aileron Therapeutics's CUSIP number?
Aileron Therapeutics's Committee on Uniform Securities Identification Procedures number is: 00887A105